Hasil Pencarian - Peter Gimsing

  • Menampilkan 1 - 9 hasil dari 9
Perbaiki Hasil
  1. 1
    A polymorphism in NFKB1 is associated with improved effect of interferon-α maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support

    A polymorphism in NFKB1 is associated with improved effect of interferon-α maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support oleh Annette J. Vangsted, Tobias W. Klausen, Peter Gimsing, Niels F. Andersen, Niels Abildgaard, Henrik Gregersen, Ulla Vogel

    Diterbitkan 2009-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease

    Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myelom... oleh Marita Westhrin, Siv Helen Moen, Toril Holien, Anne Kærsgaard Mylin, Lene Heickendorff, Oddrun Elise Olsen, Anders Sundan, Ingemar Turesson, Peter Gimsing, Anders Waage, Therese Standal

    Diterbitkan 2015-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial

    Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial oleh Hans E. Johnsen, Lene M. Knudsen, Anne K. Mylin, Peter Gimsing, Henrik Gregersen, Niels Abildgaard, Niels Frost Andersen, Torben Plesner, Annette Vangsted, Torben Mourits-Andersen

    Diterbitkan 2009-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

    Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner oleh Konstantinos Dimopoulos, Alexandra Søgaard Helbo, Helga Fibiger Munch‐Petersen, Lene Sjö, Jesper Christensen, Lasse Sommer Kristensen, Fazila Asmar, Niels Emil Ulrich Hermansen, Casey O'Connel, Peter Gimsing, Gangning Liang, Kirsten Grønbæk

    Diterbitkan 2018-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.

    Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. oleh Rasmus Sørrig, Tobias W Klausen, Morten Salomo, Annette J Vangsted, Ulf Christian Frølund, Kristian T Andersen, Anja Klostergaard, Carsten Helleberg, Robert S Pedersen, Per T Pedersen, Sissel Helm-Petersen, Elena Manuela Teodorescu, Birgitte Preiss, Niels Abildgaard, Peter Gimsing, Danish Myeloma Study Group

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

    Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple... oleh María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, Markus Hansson, Irwindeep Sandhu, Ludek Pour, Luísa Viterbo, Sharon R. Jackson, Anne-Marie Stoppa, Peter Gimsing, Mehdi Hamadani, Gabriela Borsaru, Deborah Berg, Jianchang Lin, Alessandra Di Bacco, Helgi van de Velde, Paul G. Richardson, Philippe Moreau

    Diterbitkan 2017-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

    Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials oleh Antonio Palumbo, Anders Waage, Cyrille Hulin, Meral Beksac, Sonja Zweegman, Francesca Gay, Peter Gimsing, Xavier Leleu, Pierre Wijermans, Gülsan Sucak, Sara Pezzatti, Gunnar Juliusson, Brigitte Pégourié, Martijn Schaafsma, Monica Galli, Ingemar Turesson, Brigitte Kolb, Bronno van der Holt, Ileana Baldi, Jürgen Rolke, Giovannino Ciccone, Marc Wetterwald, Henk Lokhorst, Mario Boccadoro, Philippe Rodon, Pieter Sonneveld

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

    Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial oleh Alexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, Niels Frost Andersen, Ulf Christian Frølund, Carsten Helleberg, Fredrik H. Schjesvold, Lucia Ahlberg, Nina Gulbrandsen, Bjorn Andreasson, Birgitta Lauri, Einar Haukas, Julie Støve Bødker, Anne Stidsholt Roug, Martin Bøgsted, Marianne T. Severinsen, Henrik Gregersen, Niels Abildgaard, Pieter Sonneveld, Karen Dybkær

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

    Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a... oleh Lene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette van der Velden, Wendy Deenik, Juleon Coenen, Maja Hinge, Saskia Klein, Bea Tanis, Damian Szatkowski, Rolf Brouwer, Matthijs Westerman, Rineke Leys, Harm Sinnige, Einar Haukås, Klaas van der Hem, Marc Durian, Peter Gimsing, Niels van de Donk, Pieter Sonneveld, Anders Waage, Niels Abildgaard, Sonja Zweegman

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: